Hydroxychloroquine in Untreated B-CLL Patients
| Status: | Archived |
|---|---|
| Conditions: | Blood Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | July 2008 |
| End Date: | January 2011 |
Phase II Study to Evaluate the Tolerability and Efficacy of Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients With Hydroxychloroquine.
Eligible CLL patients who sign an informed consent will be started on hydroxychloroquine
400mg po daily for up to one year. They will be monitored for disease status as well as
adverse reactions after two weeks and then every 4 weeks. Ophthalmologic exams is required
at baseline and every 6 months or sooner if the patient develops any visual disturbances.
We found this trial at
1
site
Long Island Jewish Medical Center Serving North Shore LIJ Health System employees and their families....
Click here to add this to my saved trials
